Skip to main contentSkip to navigationSkip to search

SEB initiates commissioned research on Curasight A/S

June 18, 2021


Copenhagen, Denmark, 18 June 2021 – Curasight A/S (“Curasight” or the “Company”) has entered into an agreement with Skandinaviska Enskilda Banken AB (publ) (“SEB”) on commissioned research coverage.

Starting today, SEB will initiate its commissioned research, meaning that SEB will continuously monitor and analyze Curasight’s operations, products, markets, and competitors.

The initial research report is available here


For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO

Phone: +45 22 83 01 60


Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.